- Home
- SCYX vs NDLS Comparison
SCYX vs NDLS Comparison
Compare SCYX & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- NDLS
- Stock Information
- Founded
- SCYX 1999
- NDLS 1995
- Country
- SCYX United States
- NDLS United States
- Employees
- SCYX N/A
- NDLS N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- NDLS Restaurants
- Sector
- SCYX Health Care
- NDLS Consumer Discretionary
- Exchange
- SCYX Nasdaq
- NDLS Nasdaq
- Market Cap
- SCYX 41.0M
- NDLS 34.3M
- IPO Year
- SCYX 2014
- NDLS 2013
- Fundamental
- Price
- SCYX $1.09
- NDLS $1.59
- Analyst Decision
- SCYX Buy
- NDLS Strong Buy
- Analyst Count
- SCYX 1
- NDLS 2
- Target Price
- SCYX N/A
- NDLS $3.00
- AVG Volume (30 Days)
- SCYX 214.8K
- NDLS 360.1K
- Earning Date
- SCYX 03-27-2025
- NDLS 03-06-2025
- Dividend Yield
- SCYX N/A
- NDLS N/A
- EPS Growth
- SCYX N/A
- NDLS N/A
- EPS
- SCYX N/A
- NDLS N/A
- Revenue
- SCYX $8,566,000.00
- NDLS $495,817,000.00
- Revenue This Year
- SCYX N/A
- NDLS $0.24
- Revenue Next Year
- SCYX $365.06
- NDLS $0.19
- P/E Ratio
- SCYX N/A
- NDLS N/A
- Revenue Growth
- SCYX N/A
- NDLS N/A
- 52 Week Low
- SCYX $0.90
- NDLS $0.55
- 52 Week High
- SCYX $3.07
- NDLS $2.68
- Technical
- Relative Strength Index (RSI)
- SCYX 46.40
- NDLS 81.75
- Support Level
- SCYX $1.02
- NDLS $1.30
- Resistance Level
- SCYX $1.13
- NDLS $1.55
- Average True Range (ATR)
- SCYX 0.07
- NDLS 0.16
- MACD
- SCYX 0.00
- NDLS 0.07
- Stochastic Oscillator
- SCYX 44.44
- NDLS 99.06
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.